Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Roche gets thumbs-up for KRAS test
June 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

PLEASANTON, Calif.—Roche has received U.S. Food and Drug Administration (FDA) approval for its PCR-based cobas KRAS Mutation Test for diagnostic use. The test identifies KRAS mutations in tumor samples from patients with metastatic colorectal cancer (mCRC) to help guide therapeutic decisions; more specifically, it is also meant as an aid in identifying mCRC patients who might benefit from Erbitux or Vectibix treatment if no KRAS mutation is detected.
 
“The cobas KRAS Mutation Test gives clinicians actionable insights that enable them to make informed decisions about treatment for their patient. With this approval, Roche now offers the most comprehensive companion diagnostic FDA approved portfolio for oncology in the U.S., including tests for BRAF (melanoma), EGFR (lung cancer) and KRAS (mCRC) mutations,” said Paul Brown, head of Roche Molecular Diagnostics.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.